Request More Information

Information about COAGADEX

Complete this form to receive updates about COAGADEX for hereditary factor X deficiency. This information is intended for US audiences only.

*Required

Do You Have a Question About COAGADEX?

Check this box if you would like to be contacted by someone from BPL about Coagadex.

I am a…*

Patient

Caregiver

Healthcare professional

Other (specify)

First name*

Last name*

Email*

Phone

City*

State*

Zip code*

By checking this box, you agree to receive communications relating to hereditary factor X deficiency and COAGADEX from BPL. This information will be used solely for this purpose. You can discontinue communications from BPL at any time by following the instructions on the communications.*

Indications and Usage for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:

Routine prophylaxis to reduce the frequency of bleeding episodes
On-demand treatment and control of bleeding episodes
Perioperative management of bleeding in patients with mild and moderate hereditary factor X deficiency

Limitation of Use

Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.

Contraindication for COAGADEX

COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.

Important Safety Information for COAGADEX

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.

Request More Information

Information about COAGADEX

Thank you for signing up to receive updates about COAGADEX for factor X deficiency.

Indications and Usage for COAGADEX

Contraindication for COAGADEX

Important Safety Information for COAGADEX